-

Feinstein Institutes Bioelectronic Medicine Researchers Target Specific Vagus Nerve Fibers for More Precise, Effective Stimulation

A new study published in the journal Brain Stimulation shows that high electrical frequency stimulation can activate specific nerve fibers in the body

MANHASSET, N.Y.--(BUSINESS WIRE)--Electrically stimulating the vagus nerve has shown potential to treat inflammatory diseases, including rheumatoid arthritis, lupus and diabetes. Now, a team of bioelectronic medicine scientists at The Feinstein Institutes for Medical Research is one step closer to developing more precise, selective neuromodulation techniques. A new paper published in Brain Stimulation showed that delivering high-frequency electrical stimulation activates specific sensory nerve fibers of the vagus nerve and could be the key to better targeting and treating inflammation and disease.

The research study, led by Stavros Zanos, MD, PhD, associate professor at the Feinstein Institutes Institute of Bioelectronic Medicine, measured how vagus nerve stimulation (VNS) using kHz stimulation – an electrical stimulus that is commonly used to block nerve conduction at over 1,000 pulses per second affects the activity of different types of vagal fibers. Previous VNS therapies would stimulate the whole nerve bluntly, without targeting specific fibers, which could cause adverse effects and less effective therapy. For example, in past clinical trials, side effects from the vocal cords and from coughing reflex prevented clinicians from delivering the full dose of VNS, and thus limited the therapeutic effect.

“The vagus nerve is one of the most important nerves in our body, which helps us maintain our daily functions like breathing and our heart rate. Being able to target certain nerve fibers is a huge step for precision stimulation,” said Dr. Zanos, senior author of the paper. “This selective stimulation in the vagus nerve has not been achieved until now and our results will help researchers find new therapies to treat diseases.”

The vagus nerve is made up of 100,000 individual fibers. It acts as an information pipeline in the body, stretching from the brain to the organs helping to maintain bodily functions and immune response. If the vagus nerve is overactive or underactive inflammatory diseases can arise. The field of bioelectronic medicine combines molecular medicine, neuroscience and biomedical engineering to develop innovative therapies using computer chips and devices instead of drugs to treat those diseases.

By stimulating the vagus nerve with high frequency, Dr. Zanos and his team were able to consistently activate the small unmyelinated nerve fibers while at the same time bypassing the activation of larger fibers in the nerve – which are usually the first to be activated by VNS and are responsible for most unwanted side-effects. The study was done in two animal models (mice and rats) and if validated in humans, could be leveraged in novel bioelectronic therapies.

“Dr. Zanos discovered how to selectively activate nerve fibers traveling in the vagus nerve by manipulating the electric frequency,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes and Karches Family Distinguished Chair in Medical Research. “This work significantly advances the field of bioelectronic medicine and opens new pathways to explore experimental therapeutics.”

The Feinstein Institutes for Medical Research was recently awarded $6.7 million from the National Institutes of Health (NIH). The funding will help Dr. Zanos and his lab create a detailed map of the anatomy of the human vagus nerve. The funding is part of the NIH Common Fund’s Stimulating Peripheral Activity to Relieve Conditions (SPARC) program.

About the Feinstein Institutes
The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health system science, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn.

Contacts

Julianne Mosher Allen
516-880-4824
jmosherallen@northwell.edu

The Feinstein Institutes for Medical Research


Release Versions

Contacts

Julianne Mosher Allen
516-880-4824
jmosherallen@northwell.edu

More News From The Feinstein Institutes for Medical Research

Northwell’s Feinstein Institutes’ Kevin J. Tracey named to TIME100 2026 Health list

NEW HYDE PARK, N.Y.--(BUSINESS WIRE)--In recognition of Kevin J. Tracey, MD’s decades-long pursuit into unraveling the mysteries of the brain’s connection to the body and control of inflammation through technology, TIME has named the president and CEO of the Feinstein Institutes for Medical Research at Northwell Health an “Innovator” on its 2026 TIME100 Health list. The recognition spotlights 100 of the world’s most influential leaders transforming global health. Read Dr. Tracey’s profile here...

Feinstein Institutes’ Dr. Stephanie Fitzpatrick elected Fellow of the Academy of Behavior Medicine Research

MANHASSET, N.Y.--(BUSINESS WIRE)--For her leadership in behavioral medicine and health equity, Stephanie L. Fitzpatrick, PhD, a clinical health psychologist, behavioral medicine researcher and implementation scientist at Northwell Health’s Feinstein Institutes for Medical Research, has been elected a Fellow of the Academy of Behavioral Medicine Research (ABMR), the premier honorary scientific organization in her field. The ABMR fellowship recognizes Dr. Fitzpatrick for her extensive contributio...

Northwell Invests in Mental Health, Opens Center for Psychedelics Research and Treatment

MANHASSET, N.Y.--(BUSINESS WIRE)--To address a pressing scientific and public need focused on the therapeutic potential and potential impairing effects of compounds like Δ9-THC (cannabis), psilocybin (mushrooms), MDMA (ecstasy) and ketamine, Northwell Health’s Feinstein Institutes for Medical Research today announced the official opening of the Center for Psychedelics Research and Treatment (CPRT) at Zucker Hillside Hospital in Glen Oaks. The Center will feature a state-of-the-art clinical lab,...
Back to Newsroom